AbbVie Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, July 31, 2026 at 7:50 PM GMT+3 3 min read

AbbVie Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance beat was driven by double-digit growth in SKYRIZI, RINVOQ, and the neuroscience portfolio, all exceeding 20% growth.
Management attributes SKYRIZI's psoriasis leadership to a distinct profile of durable skin clearance and superior head-to-head efficacy versus five different mechanisms.
The acquisition of Apogee Therapeutics is a strategic move to bolster the immunology pipeline with long-acting biologics for the 2030s and beyond.
Neuroscience outperformance is credited to market share gains for Vraylar and double-digit growth across the migraine portfolio (Botox, Ubrelvi, Qlipta).
Oncology results reflect a transition period where growth from newer assets like Elahere and Epkinly is partially offsetting IMBRUVICA's decline due to IRA pricing and competition.
Aesthetics headwinds in dermal fillers are being addressed through continued investment in market penetration and the launch of the short-acting toxin, BoE.

Strategic Outlook and Guidance Assumptions

Full-year revenue guidance was raised by 300 million, reflecting 600 million in total raises since the start of the year based on commercial momentum.
Management anticipates combined peak sales for RINVOQ in vitiligo and alopecia areata to approach $2 billion, significantly higher than prior expectations.
The Parkinson's portfolio, including the anticipated launch of tevapadone, is expected to achieve collective peak sales exceeding $5 billion.
Guidance assumes the Apogee transaction will close in Q3, contributing $0.14 of anticipated dilution while underlying business performance improves by $0.10.
Long-term strategy for IBD involves moving toward co-formulated combinations of SKYRIZI with novel antibodies to set new efficacy bars.

Risk Factors and Structural Dynamics

HUMIRA sales declined 36.1% operationally, a trend management describes as being in line with expectations regarding biosimilar competition.
The company is managing a net leverage ratio target of 2 times within 2 to 3 years following the close of the Apogee acquisition.
IMBRUVICA faces ongoing pressure from Medicare Inflation Reduction Act (IRA) pricing impacts and competitive share loss.
SKYRIZI regulatory data protection is noted to last until 2031, with composition of matter patents extending to 2033 and beyond.

Q&A Highlights

Impact of new oral competition on SKYRIZI psoriasis share

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management stated they have seen no degradation in new start (NBRx) trends since the launch of competitive oral therapies.
The vast majority of competitor share is being sourced from other oral treatments rather than biologics like SKYRIZI.
The market is viewed as expanding rather than zero-sum, with SKYRIZI's NBRx growth actually accelerating post-competitor launch.

Launch trajectory and formulary access for tevapadone

Expectations for the initial launch ramp are modest because the drug will not be immediately added to Medicare formularies due to negotiation timing.
Despite the slow start, management remains confident in blockbuster potential due to the drug's ability to 'pause' motor dysfunction without typical side effects like sleep attacks.

Differentiation of bretasilocin in the neuropsychiatry market

Management highlighted a shorter clinical experience (2 hours) compared to other psychedelics and a lack of 5-HT2B agonism, which avoids cardiovascular toxicity.
Dose escalation to 150mg is underway to improve receptor occupancy and address PK variability observed in earlier studies.

Strategic rationale for the PD-1/VEGF oncology program

The asset is intended to serve as a backbone for combinations with AbbVie's emerging ADC portfolio across lung and ovarian cancers.
Management plans to move rapidly into Phase 3 as a chemo-combination once optimal dosing is confirmed with regulators.